Invitae joins NIH-sponsored study aimed at improving understanding of the links between genes and cancer, heart disease and other conditions


Excerpt from the Press Release: SAN FRANCISCO, April 8, 2021 /PRNewswire/ — Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Human Genome Research Institute (NHGRI) that connects genetic data and electronic medical record (EMR) systems to advance the use of genetics…

Read More

Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma


Excerpt from the Press Release: SAN DIEGO, March 30, 2021 /PRNewswire/ — HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab),…

Read More

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma


Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Mar. 31, 2021– Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for advanced renal cell carcinoma (RCC). This approval allows for the marketing of CABOMETYX in combination with…

Read More

Cello Therapeutics’ Platelet Membrane-Coated Nanoparticles Offer a Novel Platform for the Delivery of Immunotherapy in Cancer Treatment


Excerpt from the Press Release: SAN DIEGO, March 31, 2021 (GLOBE NEWSWIRE) — Solid tumors comprise about 90% of all newly diagnosed cancer cases and cancer deaths according to an annual report from the National Cancer Institute. Despite the relative “ease” of surgical resection of such tumors, there lies significant risk in the recurrence of…

Read More

Exacis Biotherapeutics Develops mRNA-Engineered iPSC-Derived NK Cells For Difficult-To-Treat Tumors


Excerpt from the Press Release: CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ — Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, today announced several important steps in the preclinical development of its ExaNK™ engineered NK cell-therapy candidates. ExaNK™ cells are generated from induced pluripotent stem cells (iPSCs) that are made using mRNA-based cell-reprogramming and gene-editing…

Read More

USPSTF Updates Recommendation for LDCT Lung Cancer Screening


Excerpt from the Article: The U.S. Preventive Services Task Force (USPSTF) has revised its existing lung cancer screening recommendations with two major changes – its new guidance lowers screening age and incorporates patients with a shorter smoking history. Published today in JAMA, the new recommendation now calls for patients between ages 50 and 80 who…

Read More

GT Biopharma Adds University of Wisconsin–Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment


Excerpt from the Press Release: BEVERLY HILLS, Calif., March 4, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology: TriKE™ for cancer and infectious diseases, today announced the addition of a new…

Read More

Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA


Excerpt from the Press Release: OXFORDSHIRE, England and CONSHOHOCKEN, Pa. and ROCKVILLE, Md., Feb. 19, 2021 (GLOBE NEWSWIRE) — Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today…

Read More

Scientists design potential drug for triple-negative breast cancer


Excerpt from the Press Release: Scientists at Sanford Burnham Prebys Medical Discovery Institute have designed a next-generation drug, called SBP-7455, which holds promise as a treatment for triple-negative breast cancer—an aggressive cancer with limited treatment options. The drug blocks a cellular recycling process called autophagy, which cancer cells hijack as a way to resist treatment.…

Read More

How to Handle a COVID-19 Vaccine-Related Adenopathy Seen on Breast MRI


Excerpt from the Article: The Hospital of the University of Pennsylvania offers guidance – BI-RADS scoring and follow-up recommendations – for unilateral axillary lymphadenopathies seen on breast MRI in women who have received the vaccine. The baseline breast MRI of a 48-year-old woman who has the BRCA1 mutation, as well as a strong family history…

Read More